{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:18:37Z","timestamp":1761513517982,"version":"3.40.5"},"reference-count":33,"publisher":"American Academy of Pediatrics (AAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,10,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVES:<\/jats:title>\n                  <jats:p>Given the improved efficacy of the nasal live-attenuated influenza virus vaccine (LAIV) compared with the injectable vaccine in children, we aimed to determine its safety in individuals with cystic fibrosis (CF).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS:<\/jats:title>\n                  <jats:p>A cohort of 168 study participants, aged 2 to 18 years with CF, vaccinated with LAIV between October 1, 2012, and January 30, 2013, was followed prospectively for 56 days after initial vaccination in 3 pediatric CF clinics across the province of Quebec. Days 0 to 28 post-LAIV were considered the at-risk period for all outcomes of interest, and days 29 to 56 post-LAIV were considered the non\u2013at-risk period. Incident respiratory deteriorations were defined as an unscheduled medical visit, hospitalization, or a new course of oral antibiotics for respiratory complaints. Using a self-controlled design, incidence rate ratios (IRR) were used to compare at-risk and non\u2013at-risk periods.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS:<\/jats:title>\n                  <jats:p>Comparing at-risk to non\u2013at-risk periods, there was no significant increase in the rate of incident respiratory deteriorations (IRR, 0.72; 95% confidence interval, 0.11\u20134.27) or all-cause hospitalizations (IRR, 1.16; 95% confidence interval, 0.30\u20134.81). A greater proportion of participants reported experiencing at least 1 minor respiratory and\/or systemic adverse event after immunization during the at-risk period compared with the non\u2013at-risk period (77% vs 54%, respectively). During the first week after LAIV, 13 of 168 (8%) children reported some wheezing, with the vast majority, 9 of 13 (69%), on the day of vaccination.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS:<\/jats:title>\n                  <jats:p>There was no increased risk of respiratory deterioration or all-cause hospitalization associated with LAIV in our study population. LAIV seems well tolerated in children and adolescents with CF.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1542\/peds.2014-0887","type":"journal-article","created":{"date-parts":[[2014,9,16]],"date-time":"2014-09-16T04:36:33Z","timestamp":1410842193000},"page":"e983-e991","source":"Crossref","is-referenced-by-count":13,"title":["Safety of Live-Attenuated Influenza Vaccination in Cystic Fibrosis"],"prefix":"10.1542","volume":"134","author":[{"given":"Constantina","family":"Boikos","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaston","family":"De Serres","sequence":"additional","affiliation":[{"name":"Department of Social and Preventive Medicine, Laval University, Quebec City, Canada;"},{"name":"Institut national de sant\u00e9 publique du Qu\u00e9bec, Quebec, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry C.","family":"Lands","sequence":"additional","affiliation":[{"name":"Divisions of Respiratory Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois D.","family":"Boucher","sequence":"additional","affiliation":[{"name":"Divisions of Infectious Diseases, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"Tapi\u00e9ro","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Pediatrics, CHU Sainte-Justine, Montreal, Canada; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Daigneault","sequence":"additional","affiliation":[{"name":"Respiratory Medicine, Department of Pediatrics, Centre M\u00e8re-Enfant Soleil du CHU de Qu\u00e9bec, Quebec, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Quach","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Canada;"},{"name":"Institut national de sant\u00e9 publique du Qu\u00e9bec, Quebec, Canada;"},{"name":"Infectious Diseases, Department of Pediatrics, The Montreal Children\u2019s Hospital, McGill University, Montreal, Canada;"},{"name":"McGill University Health Centre, Vaccine Study Centre, Research Institute of the MUHC, Montreal, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2014,10,1]]},"reference":[{"issue":"3","key":"2021120903435335500_B1","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jpeds.2005.06.043","article-title":"Cystic fibrosis birth rates in Canada: a decreasing trend since the onset of genetic testing.","volume":"147","author":"Dupuis","year":"2005","journal-title":"J Pediatr"},{"issue":"6 pt 1","key":"2021120903435335500_B2","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1164\/ajrccm.152.6.8520783","article-title":"Inflammatory cytokines in cystic fibrosis lungs.","volume":"152","author":"Bonfield","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"2021120903435335500_B3","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1164\/ajrccm.160.1.9808096","article-title":"Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients.","volume":"160","author":"Muhlebach","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"2021120903435335500_B4","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/ppul.20010","article-title":"Quantitative cytokine gene expression in CF airway.","volume":"37","author":"Muhlebach","year":"2004","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"2021120903435335500_B5","doi-asserted-by":"crossref","first-page":"L493","DOI":"10.1152\/ajplung.2001.280.3.L493","article-title":"Proinflammatory cytokine responses to P. aeruginosa infection in human airway epithelial cell lines.","volume":"280","author":"Kube","year":"2001","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"7","key":"2021120903435335500_B6","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/thx.2008.096834","article-title":"Prolonged survival of neutrophils from patients with Delta F508 CFTR mutations.","volume":"63","author":"McKeon","year":"2008","journal-title":"Thorax"},{"issue":"4","key":"2021120903435335500_B7","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jcf.2007.12.002","article-title":"The role of respiratory viruses in cystic fibrosis.","volume":"7","author":"Wat","year":"2008","journal-title":"J Cyst Fibros"},{"issue":"2","key":"2021120903435335500_B8","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1136\/thx.47.2.112","article-title":"Acute severe deterioration in cystic fibrosis associated with influenza A virus infection.","volume":"47","author":"Conway","year":"1992","journal-title":"Thorax"},{"issue":"5","key":"2021120903435335500_B9","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1440-1754.1991.tb02545.x","article-title":"Impact of influenza on morbidity in children with cystic fibrosis.","volume":"27","author":"Ferson","year":"1991","journal-title":"J Paediatr Child Health"},{"issue":"2","key":"2021120903435335500_B10","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1136\/adc.73.2.117","article-title":"Effect of respiratory virus infections including rhinovirus on clinical status in cystic fibrosis.","volume":"73","author":"Smyth","year":"1995","journal-title":"Arch Dis Child"},{"issue":"6","key":"2021120903435335500_B11","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1542\/peds.2007-3139","article-title":"Prevalence and impact of respiratory viral infections in young children with cystic fibrosis: prospective cohort study.","volume":"122","author":"van Ewijk","year":"2008","journal-title":"Pediatrics"},{"issue":"1","key":"2021120903435335500_B12","doi-asserted-by":"crossref","first-page":"e78583","DOI":"10.1371\/journal.pone.0078583","article-title":"Influenza A(H1N1)pdm09 and cystic fibrosis lung disease: a systematic meta-analysis.","volume":"9","author":"Renk","year":"2014","journal-title":"PLoS ONE"},{"key":"2021120903435335500_B13"},{"key":"2021120903435335500_B14"},{"issue":"7","key":"2021120903435335500_B15","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJMoa065368","article-title":"Live attenuated versus inactivated influenza vaccine in infants and young children.","volume":"356","author":"Belshe","year":"2007","journal-title":"N Engl J Med"},{"key":"2021120903435335500_B16","unstructured":"Protocole d\u2019immunisation du Qu\u00e9bec. 2013. Available at: http:\/\/publications.msss.gouv.qc.ca\/acrobat\/f\/documentation\/piq\/piq_complet.pdf. Accessed on March 15, 2014."},{"issue":"1","key":"2021120903435335500_B17","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cct.2013.06.004","article-title":"Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials.","volume":"36","author":"Mayer-Hamblett","year":"2013","journal-title":"Contemp Clin Trials"},{"issue":"2","key":"2021120903435335500_B18","first-page":"CD000364","article-title":"Vaccines for preventing influenza in people with asthma.","author":"Cates","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"2021120903435335500_B19","first-page":"CD001753","article-title":"Vaccines for preventing influenza in people with cystic fibrosis.","author":"Dharmaraj","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"2021120903435335500_B20","unstructured":"Report of Adverse Events Following Immunization. 2013. Available at: www.phac-aspc.gc.ca\/im\/aefi-essi-form-desc-eng.php. Accessed on March 15, 2014."},{"key":"2021120903435335500_B21","first-page":"349","article-title":"P, Mullooly J, McClure D, Hambidge SJ, Glanz J. Fitting parametric and semi-parametric conditional poisson regression models with Cox\u2019s partial likelihood in self-controlled case series and matched cohort studies.","volume":"8(2010)","author":"Xu","year":"2010","journal-title":"J Data Sci."},{"issue":"10","key":"2021120903435335500_B22","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/sim.2302","article-title":"Tutorial in biostatistics: the self-controlled case series method.","volume":"25","author":"Whitaker","year":"2006","journal-title":"Stat Med"},{"key":"2021120903435335500_B23"},{"key":"2021120903435335500_B24"},{"issue":"5","key":"2021120903435335500_B25","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1128\/AAC.44.5.1163-1167.2000","article-title":"Comparison of immunogenicity and safety of a virosome influenza vaccine with those of a subunit influenza vaccine in pediatric patients with cystic fibrosis.","volume":"44","author":"Schaad","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"issue":"21","key":"2021120903435335500_B26","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1001\/jama.294.21.2720","article-title":"Adverse events reported following live, cold-adapted, intranasal influenza vaccine.","volume":"294","author":"Izurieta","year":"2005","journal-title":"JAMA"},{"issue":"5","key":"2021120903435335500_B27","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/INF.0b013e3181660c2e","article-title":"Safety of the intranasal, trivalent, live attenuated influenza vaccine (LAIV) in children with intermittent wheezing in an open-label field trial.","volume":"27","author":"Gaglani","year":"2008","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"2021120903435335500_B28","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1086\/367667","article-title":"Oculo-respiratory syndrome: a new influenza vaccine-associated adverse event?","volume":"36","author":"Skowronski","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"6","key":"2021120903435335500_B29","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1542\/peds.2005-2607","article-title":"Solicited adverse events after influenza immunization among infants, toddlers, and their household contacts.","volume":"117","author":"Skowronski","year":"2006","journal-title":"Pediatrics"},{"issue":"12","key":"2021120903435335500_B30","doi-asserted-by":"crossref","first-page":"e27897","DOI":"10.1371\/journal.pone.0027897","article-title":"Adverse events following 12 and 18 month vaccinations: a population-based, self-controlled case series analysis.","volume":"6","author":"Wilson","year":"2011","journal-title":"PLoS ONE"},{"issue":"12","key":"2021120903435335500_B31","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1017\/S0950268811001531","article-title":"Use of the self-controlled case-series method in vaccine safety studies: review and recommendations for best practice.","volume":"139","author":"Weldeselassie","year":"2011","journal-title":"Epidemiol Infect"},{"key":"2021120903435335500_B32","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/pds.2330","article-title":"When should case-only designs be used for safety monitoring of medical products?","volume":"21","author":"Maclure","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"12","key":"2021120903435335500_B33","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/aje\/kwt211","article-title":"Bias correction of risk estimates in vaccine safety studies with rare adverse events using a self-controlled case series design.","volume":"178","author":"Zeng","year":"2013","journal-title":"Am J Epidemiol"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/134\/4\/e983\/1099693\/peds_2014-0887.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/134\/4\/e983\/1099693\/peds_2014-0887.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T19:23:34Z","timestamp":1639077814000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/134\/4\/e983\/32948\/Safety-of-Live-Attenuated-Influenza-Vaccination-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,1]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,10,1]]},"published-print":{"date-parts":[[2014,10,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2014-0887","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"type":"print","value":"0031-4005"},{"type":"electronic","value":"1098-4275"}],"subject":[],"published":{"date-parts":[[2014,10,1]]}}}